Jeffrey S McCombs

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. ncbi request reprint The impact of unrecognized bipolar disorders among patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program: a 6-year retrospective analysis
    Jeffrey S McCombs
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA 90089 9004, USA
    J Affect Disord 97:171-9. 2007
  2. doi request reprint Applying comparative effectiveness research methods in bipolar disorders
    Jeffrey S McCombs
    Department of Clinical Pharmacy and Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, 1540 E Alcazar St, Rm CHP 140, Los Angeles, CA 90080 9004, United States
    J Affect Disord 130:145-54. 2011
  3. ncbi request reprint Open access to innovative drugs: treatment substitutions or treatment expansion?
    Jeffrey S McCombs
    Department of Pharmaceutical Economics and Policy School of Pharmacy, University of Southern California, USA
    Health Care Financ Rev 25:35-53. 2004
  4. ncbi request reprint Compliance with drug therapies for the treatment and prevention of osteoporosis
    Jeffrey S McCombs
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
    Maturitas 48:271-87. 2004
  5. doi request reprint Impact of drug treatment history on comparative effectiveness research in schizophrenia
    Jeffrey McCombs
    Department of Clinical Pharmacy and Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA 90089 9004, USA
    Value Health 14:679-86. 2011
  6. doi request reprint Economic burden associated with patients diagnosed with hepatitis C
    Jeffrey S McCombs
    School of Pharmacy, University of Southern California, Los Angeles, 90089 9004, USA
    Clin Ther 33:1268-80. 2011
  7. ncbi request reprint Access to drug therapy and substitution between alternative antidepressants following an expansion of the California Medicaid formulary
    Jeffrey S McCombs
    Department of Pharmaceutical Economics and Policy, USC School of Pharmacy, University of Southern California, 1540 E Alcazar St, Rm CHP 140, Los Angeles, CA 90033, USA
    Health Policy 65:301-11. 2003
  8. doi request reprint Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program
    Jeonghoon Ahn
    University of Southern California, Los Angeles, CA, USA
    Value Health 11:48-56. 2008
  9. ncbi request reprint A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder
    Jeffrey S McCombs
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA 90033, USA
    Clin Ther 24:1939-59; discussion 1938. 2002
  10. doi request reprint Duration of antipsychotic drug therapy in real-world practice: a comparison with CATIE trial results
    Lei Chen
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
    Value Health 11:487-96. 2008

Detail Information

Publications19

  1. ncbi request reprint The impact of unrecognized bipolar disorders among patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program: a 6-year retrospective analysis
    Jeffrey S McCombs
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA 90089 9004, USA
    J Affect Disord 97:171-9. 2007
    ..The cost of unrecognized bipolar disorders over time is unknown...
  2. doi request reprint Applying comparative effectiveness research methods in bipolar disorders
    Jeffrey S McCombs
    Department of Clinical Pharmacy and Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, 1540 E Alcazar St, Rm CHP 140, Los Angeles, CA 90080 9004, United States
    J Affect Disord 130:145-54. 2011
    ..This paper demonstrates how observational CER can fill important gaps in clinical knowledge left behind by RCT approaches. An example of CER in bipolar disorders is presented...
  3. ncbi request reprint Open access to innovative drugs: treatment substitutions or treatment expansion?
    Jeffrey S McCombs
    Department of Pharmaceutical Economics and Policy School of Pharmacy, University of Southern California, USA
    Health Care Financ Rev 25:35-53. 2004
    ..Program administrators must use caution when evaluating the impact of unrestricted access on drug therapy outcomes and treatment costs given the changes in the characteristics of patients seeking treatment...
  4. ncbi request reprint Compliance with drug therapies for the treatment and prevention of osteoporosis
    Jeffrey S McCombs
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
    Maturitas 48:271-87. 2004
    ..This study used paid claims data from real-world treatment settings to investigate the impact of hormone replacement therapy (HRT), bisphosphonate and raloxifene on patients with a recorded diagnosis of osteoporosis...
  5. doi request reprint Impact of drug treatment history on comparative effectiveness research in schizophrenia
    Jeffrey McCombs
    Department of Clinical Pharmacy and Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA 90089 9004, USA
    Value Health 14:679-86. 2011
    ..Observational research has the potential to compare alternative treatments under a wider range of clinical situations if care is taken to document each patient's treatment history...
  6. doi request reprint Economic burden associated with patients diagnosed with hepatitis C
    Jeffrey S McCombs
    School of Pharmacy, University of Southern California, Los Angeles, 90089 9004, USA
    Clin Ther 33:1268-80. 2011
    ..Data documenting the incremental economic and health burden of patients with HCV relative to those who are not infected with HCV will be required to evaluate the comparative effectiveness of these new therapies...
  7. ncbi request reprint Access to drug therapy and substitution between alternative antidepressants following an expansion of the California Medicaid formulary
    Jeffrey S McCombs
    Department of Pharmaceutical Economics and Policy, USC School of Pharmacy, University of Southern California, 1540 E Alcazar St, Rm CHP 140, Los Angeles, CA 90033, USA
    Health Policy 65:301-11. 2003
    ..However, while some expansion in overall antidepressant use may have been desired, the clinical validity of this expansion cannot be determined based on the results presented here...
  8. doi request reprint Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program
    Jeonghoon Ahn
    University of Southern California, Los Angeles, CA, USA
    Value Health 11:48-56. 2008
    ..This study identifies latent classes defined by varying degrees of adherence to antipsychotic drug therapy and examines the sociodemographic, clinical, and resource utilization correlates associated with membership in each adherence class...
  9. ncbi request reprint A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder
    Jeffrey S McCombs
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA 90033, USA
    Clin Ther 24:1939-59; discussion 1938. 2002
    ..The California Medicaid (Medi-Cal) program removed prior authorization restrictions for 2 selective serotonin reuptake inhibitors (SSRIs), fluoxetine and paroxetine, in May 1996...
  10. doi request reprint Duration of antipsychotic drug therapy in real-world practice: a comparison with CATIE trial results
    Lei Chen
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
    Value Health 11:487-96. 2008
    ..This study compares the TTAD achieved when using alternative antipsychotics to treat patients with schizophrenia in real-world practice settings...
  11. doi request reprint The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia
    Lei Chen
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
    Value Health 11:34-43. 2008
    ..Using data in real-world clinical practice, this study aims to compare the health-care use patterns of patients with schizophrenia who use oral antipsychotics...
  12. ncbi request reprint Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) program
    Jinmei Li
    Department of Pharmaceutical Economics and Policy, University of Southern California School of Pharmacy, 1540 E Alcazar St, Rm CHP 140, Los Angeles, CA 90033, USA
    J Affect Disord 71:131-9. 2002
    ..The objective of this study was to document the use patterns with mood stabilizers achieved by patients with bipolar disorder and to estimate the direct health care costs associated with sub-optimal drug therapy...
  13. pmc A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study
    Danielle C Colayco
    University of Southern California School of Pharmacy, Department of Pharmaceutical Economics and Policy, Los Angeles, California, USA
    Diabetes Care 34:77-83. 2011
    ..The role of aggressive glycemic control in preventing cardiovascular events is unclear. A nested case-control study design was used to evaluate the association between average A1C and cardiovascular outcomes...
  14. doi request reprint Effect of exenatide, pen insulin, and vial insulin on patient outcomes: a retrospective database analysis of persistence and first-year costs in a commercially insured population
    Nazia Rashid
    Department of Clinical Pharmacy and Pharmaceutical Economics and Policy, Leonard Schaeffer Center for Health Policy and Economics, School of Pharmacy, University of Southern California, Los Angeles, California, USA
    Clin Ther 34:1145-58. 2012
    ..We compared health care costs and medication persistence for patients with type 2 diabetes initiating treatment using exenatide, pen insulin, or vial insulin...
  15. doi request reprint The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system
    Janet Shin
    Pharmacy Analytical Services, Kaiser Permanente Southern California, Downey, California, USA
    J Am Acad Dermatol 65:1117-25. 2011
    ..The iPLEDGE program is the latest in a series of Food and Drug Administration-mandated risk management programs designed to prevent pregnancies in female patients of childbearing potential (FCBP) taking isotretinoin...
  16. ncbi request reprint The impact of unrecognized bipolar disorders for patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program
    Lizheng Shi
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Affect Disord 82:373-83. 2004
    ..This study compares hospital use, suicide risk and health care costs of antidepressant patients with recognized bipolar disorders (recognized-BP) and unrecognized bipolar disorders (unrecognized-BP) with non-bipolar (non-BP) patients...
  17. ncbi request reprint Effects of ambulatory-care pharmacist consultation on mortality and hospitalization
    Yong Yuan
    Global Epidemiology Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA
    Am J Manag Care 9:45-56. 2003
    ..To determine the effect of 3 alternative models of ambulatory-care pharmacist consultation on patient survival and hospitalization...
  18. ncbi request reprint Defining and measuring clinical effectiveness in the treatment of schizophrenia
    Henry A Nasrallah
    Department of Psychiatry, University of Cincinnati Medical Center, Cincinnati, Ohio 45267 0559, USA
    Psychiatr Serv 56:273-82. 2005
    ..This report describes an approach to define and measure the clinical effectiveness of treatment in achieving these objectives...
  19. ncbi request reprint Can pharmacy data improve prediction of hospital outcomes? Comparisons with a diagnosis-based comorbidity measure
    Joseph P Parker
    Health Care Quality and Analysis Division, California Office of Statewide Health Planning and Development, Sacramento 95814, USA
    Med Care 41:407-19. 2003
    ....